Abstract
Epidermal Growth Factor Receptor (EGFR) mutations are critical biomarkers for targeted therapies in non-small cell lung cancer (NSCLC). However, conventional diagnostic methods rely on invasive tissue biopsies, which are costly, time-consuming, and pose significant limitations. As an alternative, non-invasive approaches using lung CT imaging to predict EGFR mutation status have gained attention for their rapid and user-friendly nature. This study explores EGFR mutation prediction by analyzing seven distinct 2D regions of interest (ROI): the nodule itself, 2-pixel, 4-pixel, and 6-pixel extensions around the nodule, CT slices containing the nodule, single-lung segmented images with the nodule, and bilateral lung segmented images with the nodule. We developed a deep learning model combining EfficientNet-B0 with a Coordinate Attention (CA) mechanism, replacing the traditional MLP classifier with a KAN classifier. Results show that analyzing single-lung images containing the nodule captures additional relevant information, achieving the highest predictive performance. This suggests that regions surrounding the nodule contain valuable discriminatory biomarkers. The model achieved 92.73% accuracy on the single-lung test set with only 6.82M parameters, demonstrating its potential as a clinical tool to optimize targeted treatment decision-making.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The datasets used in this paper are all publicly available datasets.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
★ This document is the results of the research project funded by Natural Science Foundation of Inner Mongolia Autonomous Region, grant number: 2023QN06007.
